Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADH-1 + carboplatin
- Development stage
- Unknown
- Lead developer
- Fennec Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
ADH-1 + carboplatin is an investigational combination therapy consisting of ADH-1 (Exherin), a small molecule competitive inhibitor of N-cadherin, and carboplatin, a platinum-based alkylating chemotherapeutic agent. ADH-1 targets N-cadherin on tumor cells and vasculature to disrupt cell adhesion and induce tumor vascular angiolysis and apoptosis. It has shown potential anti-tumor activity in preclinical models and early clinical studies for tumors expressing N-cadherin. Carboplatin exerts its cytotoxic effect by forming DNA crosslinks that inhibit DNA replication and transcription, leading to cell death. The combination is being evaluated in early-phase clinical trials for synergistic anti-tumor effects in various solid tumors[1][2][4].
- Other names
- ADH-1 + carboplatin
02
Targets
DNACDH2 (N-cadherin)
Beyond the preview
Go deeper on ADH-1 + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADH-1 + carboplatin.